- Home
- SOPH vs NBTX Comparison
SOPH vs NBTX Comparison
Compare SOPH & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOPH
- NBTX
- Stock Information
- Founded
- SOPH 2011
- NBTX 2003
- Country
- SOPH Switzerland
- NBTX France
- Employees
- SOPH N/A
- NBTX N/A
- Industry
- SOPH Biotechnology: Biological Products (No Diagnostic Substances)
- NBTX Biotechnology: Pharmaceutical Preparations
- Sector
- SOPH Health Care
- NBTX Health Care
- Exchange
- SOPH Nasdaq
- NBTX Nasdaq
- Market Cap
- SOPH 247.0M
- NBTX 235.6M
- IPO Year
- SOPH 2021
- NBTX 2020
- Fundamental
- Price
- SOPH $3.47
- NBTX $4.96
- Analyst Decision
- SOPH Strong Buy
- NBTX Strong Buy
- Analyst Count
- SOPH 3
- NBTX 2
- Target Price
- SOPH $7.00
- NBTX $11.50
- AVG Volume (30 Days)
- SOPH 31.4K
- NBTX 13.1K
- Earning Date
- SOPH 11-05-2024
- NBTX 10-15-2024
- Dividend Yield
- SOPH N/A
- NBTX N/A
- EPS Growth
- SOPH N/A
- NBTX N/A
- EPS
- SOPH N/A
- NBTX N/A
- Revenue
- SOPH $64,938,000.00
- NBTX $45,220,186.00
- Revenue This Year
- SOPH $7.70
- NBTX N/A
- Revenue Next Year
- SOPH $20.61
- NBTX N/A
- P/E Ratio
- SOPH N/A
- NBTX N/A
- Revenue Growth
- SOPH 20.14
- NBTX 526.17
- 52 Week Low
- SOPH $2.70
- NBTX $4.14
- 52 Week High
- SOPH $7.37
- NBTX $8.96
- Technical
- Relative Strength Index (RSI)
- SOPH 41.09
- NBTX 47.92
- Support Level
- SOPH $3.03
- NBTX $4.93
- Resistance Level
- SOPH $3.50
- NBTX $5.36
- Average True Range (ATR)
- SOPH 0.25
- NBTX 0.36
- MACD
- SOPH -0.06
- NBTX -0.00
- Stochastic Oscillator
- SOPH 27.48
- NBTX 36.44
About SOPH SOPHiA GENETICS SA
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.
About NBTX Nanobiotix S.A.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.